Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Operating Expenses (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Operating Expenses for 4 consecutive years, with $223.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 16.5% to $223.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $805.3 million through Dec 2025, up 20.86% year-over-year, with the annual reading at $805.3 million for FY2025, 20.86% up from the prior year.
  • Operating Expenses hit $223.0 million in Q4 2025 for Axsome Therapeutics, up from $217.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $223.0 million in Q4 2025 to a low of $38.3 million in Q1 2022.
  • Historically, Operating Expenses has averaged $137.7 million across 4 years, with a median of $153.7 million in 2024.
  • Biggest five-year swings in Operating Expenses: skyrocketed 163.65% in 2023 and later rose 12.71% in 2024.
  • Year by year, Operating Expenses stood at $84.3 million in 2022, then soared by 101.45% to $169.8 million in 2023, then rose by 12.71% to $191.4 million in 2024, then increased by 16.5% to $223.0 million in 2025.
  • Business Quant data shows Operating Expenses for AXSM at $223.0 million in Q4 2025, $217.1 million in Q3 2025, and $186.8 million in Q2 2025.